CC News

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired The Chemours Company (Chemours or the Company) (NYSE: CC) common stock between February 20, 2026 and August 4, 2026, inclusive (the Class Period...

Chemours (NYSE:CC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entireread more...

Investors need to pay close attention to CC stock based on the movements in the options market lately.

GuideAI Health uses FDA-cleared artificial intelligence to help identify vascular disease earlier, supporting faster diagnosis and improved patient care. Vascular disease affects millions of Americans and is estimated to cost the U.S. healthcare system more than $500 billion annually*. Early detection remains one of the biggest challenges, as many patients are diagnosed only after the disease has progressed. GuideAI Health is addressing this need through FDA-cleared artificial intelligence designed to help clinicians detect vascular disease sooner and support earlier intervention. By combining AI-powered screening with existing clinical workflows, GuideAI Health aims to improve diagnostic efficiency while helping healthcare providers identify at-risk patients more quickly. As healthcare systems continue adopting artificial intelligence to improve outcomes and reduce costs, the company is positioning at the intersection of digital health, preventative care, and medical technology. For more information on GuideAI Health, please click the requestinvestor info button. *Estimated annual U.S. healthcare costs associated with vascular disease. Source: J Am Heart Assoc. 2018. ‍

Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz...

Chemours Publishes 2025 Sustainability Report Highlighting Progress on Climate, Emissions Reduction, and Responsible Manufacturing Chemours Publishes 2025 Sustainability Report Highlighting Progress on Climate, Emissions Reduction, and Responsible Manufacturing PR Newswire WILMINGTON, Del., Aug...

TiO2 price pressure remains a headwind for Kronos Worldwide as lower selling prices offset volume gains and cost savings.

CC expands its low-GWP Opteon refrigerant portfolio to meet rising cooling needs from AI-driven data centers and support decarbonization goals.